Literature DB >> 16901622

A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer.

Steven Joniau1, Chao-Yu Hsu, Evelyne Lerut, Anthony Van Baelen, Karin Haustermans, Tania Roskams, Raymond Oyen, Hein Van Poppel.   

Abstract

OBJECTIVES: Partin tables are the most widely used tool to predict histopathologic stage after radical prostatectomy (RP) in organ-confined tumors. Such a predictive table in clinical T3 disease is still lacking. Our objective was to create a reference table for clinical unilateral T3a prostate cancer. PATIENTS AND METHODS: Between 1987 and 2004, 200 patients with clinical unilateral T3a disease underwent a RP and bilateral pelvic lymphadenectomy at our institution. No patient had received neoadjuvant treatment. Patients were divided into three prostate-specific antigen (PSA) subgroups (<or=10 ng/ml, >10-20 ng/ml, and >20 ng/ml) and two biopsy Gleason sum (GS) subgroups (<or=7 [3+4] and >or=7 [4+3]). These parameters were used in the table as predictors for final histopathology. Margin and nodal status were also recorded. The multinomial log-linear regression analysis was used to construct the table.
RESULTS: The table stratifies patients into six demarcated risk groups. In the first group, consisting of patients with PSA <or=10 and GS <or=7 (3+4), understaging was only 6% (5% pT3b and 1% pT4). The risk for understaging cT3a prostate cancer increases further with increasing PSA and GS. In the sixth group, consisting of patients with PSA >20 and GS >or=7 (4+3), understaging was as high as 68% (44% pT3b and 22% pT4). Receiver operating characteristic analyses showed good accurate predictive ability of the table for seminal vesicle involvement and adjacent structure involvement, with moderate predictive ability for extraprostatic extension only.
CONCLUSIONS: We present a table combining preoperative serum PSA and biopsy GS to predict histopathologic results in clinical unilateral T3a prostate cancer. The table may provide a basis for decision-making and patient counseling before treating this cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16901622     DOI: 10.1016/j.eururo.2006.06.051

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  11 in total

Review 1.  Biomarker research in prostate cancer--towards utility, not futility.

Authors:  Sheng Fei Oon; Stephen R Pennington; John M Fitzpatrick; R William G Watson
Journal:  Nat Rev Urol       Date:  2011-03       Impact factor: 14.432

2.  Role of surgery in high-risk localized prostate cancer.

Authors:  N Lawrentschuk; G Trottier; C Kuk; A R Zlotta
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

3.  Multimodal approaches to high-risk prostate cancer.

Authors:  A Koupparis; M E Gleave
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

4.  Integration of MRI to clinical nomogram for predicting pathological stage before radical prostatectomy.

Authors:  Cedric Lebacle; Françoise Roudot-Thoraval; Anissa Moktefi; Mohamed Bouanane; Alexandre De La Taille; Laurent Salomon
Journal:  World J Urol       Date:  2016-12-19       Impact factor: 4.226

Review 5.  Radical Prostatectomy for Locally Advanced Prostate Cancers-Review of Literature.

Authors:  N Srivatsa; H Nagaraja; S Shweta; S K Raghunath
Journal:  Indian J Surg Oncol       Date:  2017-01-05

6.  Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?

Authors:  Hye Won Lee; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

7.  Complications and functional results of surgery for locally advanced prostate cancer.

Authors:  S G Joniau; A A Van Baelen; C Y Hsu; H P Van Poppel
Journal:  Adv Urol       Date:  2012-01-12

Review 8.  Locally advanced and high risk prostate cancer: The best indication for initial radical prostatectomy?

Authors:  Hendrik van Poppel
Journal:  Asian J Urol       Date:  2015-04-16

Review 9.  The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making.

Authors:  Thomas Van den Broeck; Steven Joniau; Liesbeth Clinckemalie; Christine Helsen; Stefan Prekovic; Lien Spans; Lorenzo Tosco; Hendrik Van Poppel; Frank Claessens
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

10.  TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.

Authors:  Zoran Krstanoski; Nadja Kokalj Vokac; Andreja Zagorac; Boris Pospihalj; Miha Munda; Saso Dzeroski; Rastko Golouh
Journal:  BMC Urol       Date:  2016-07-04       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.